

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of June 2023

| | 30.06.2023 | 31.12.2022 |
|--------------------------------------|-------------------|-------------------|
| | <i>BGN'000</i> | <i>BGN'000</i> |
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 34 583 | 35 319 |
| Intangible assets | 3 581 | 3 761 |
| Investments in subsidiaries | 19 | 19 |
| Trade receivables | 5 076 | 5 076 |
| Total non-current assets | 43 259 | 44 175 |
| Current assets | | |
| Inventories | 12 876 | 13 480 |
| Trade and other receivables | 65 425 | 62 056 |
| Current corporate income tax | - | 27 |
| Cash and cash equivalents | 109 | 126 |
| Total current assets | 78 410 | 75 689 |
| Total assets | 121 669 | 119 864 |
| LIABILITIES | | |
| Equity | | |
| Share capital | 84 500 | 84 500 |
| Reserves | 12 782 | 12 498 |
| Retained earnings | 8 589 | 4 591 |
| Total | 105 871 | 101 589 |
| Non-current liabilities | | |
| Long-term loans | 1 168 | 1 399 |
| Deferred tax liabilities | 1 042 | 1 042 |
| Retirement benefit obligations | 191 | 191 |
| Total non-current liabilities | 2 401 | 2 632 |
| Current liabilities | | |
| Trade and other liabilities | 2 710 | 5 079 |
| Short-term loans | 9 788 | 9 785 |
| Current portion of long-term loans | 501 | 620 |
| Other tax liabilities | 398 | 159 |
| Total current liabilities | 13 397 | 15 643 |
| Total liabilities | 15 798 | 18 275 |
| Total equity and liabilities | 121 669 | 119 864 |

Date of preparation: 25.07.2023

Sofia

Prepared by:.....
 / P. Moneva /

Executive Director:.....
 /B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of June 2023

| | 30.06.2023 | 30.06.2022 |
|--|-----------------------|-----------------------|
| | <i>BGN'000</i> | <i>BGN'000</i> |
| Revenue | 25 781 | 22 668 |
| Other income | 61 | 313 |
| Total income | 25 842 | 22 981 |
| Carrying amount of goods sold | (763) | (329) |
| Changes in inventories of finished products and work in progress | 354 | (626) |
| Materials and services | (15 367) | (14 294) |
| Personnel expenses | (3 117) | (2 769) |
| Depreciation / amortisation expenses | (1 576) | (1 825) |
| Other expenses | (613) | (198) |
| Finance income | 40 | 23 |
| Finance costs | (308) | (196) |
| Total expenses | (21 350) | (20 214) |
| Profit before taxation | 4 492 | 2 767 |
| Corporate income tax expense | (210) | (180) |
| Profit/Loss for the period | 4 282 | 2 587 |
| Total comprehensive income for the period | 4 282 | 2 587 |
| Earnings per share / in BGN per 1 share / | 0.05 | 0.02 |

Date of preparation: 25.07.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....


/B. Georgiev/


Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of June 2023

| | 30.06.2023 | 30.06.2022 |
|---|-------------------|-------------------|
| | <i>BGN'000</i> | <i>BGN'000</i> |
| Cash flows from operating activities | | |
| Proceeds from sale of finished products, goods and services | 16 816 | 15 203 |
| Payments to suppliers of materials, goods and services | (8 791) | (8 615) |
| Payments to personnel | (3 207) | (2 845) |
| Foreign currency exchange gains/losses | (12) | (24) |
| Payments of interest and dividends | (183) | (265) |
| Other proceeds / payments | (3 077) | (2 598) |
| <i>Net cash flows</i> | 1 546 | 856 |
| Cash flows from investing activities | | |
| Payments on non-current assets acquired | (1 079) | (507) |
| <i>Net cash flows</i> | (1 079) | (507) |
| Cash flows from financial activities | | |
| Proceeds from loans | 222 | 98 |
| Payments on loans | (223) | (97) |
| Payment of interest, dividends | (222) | (103) |
| Payments on finance lease | (261) | (261) |
| <i>Net cash flows</i> | (484) | (363) |
| Change in cash and cash equivalents | (17) | (14) |
| Cash and cash equivalents at the beginning of the period | 126 | 40 |
| Cash and cash equivalents at the end of the period | 109 | 26 |

Date of preparation: 25.07.2023

Sofia

Prepared by:.....

 / P. Moneva /

Executive
 Director:.....

 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of June 2023

| | Registered (share) capital <i>BGN'000</i> | Revaluation reserves <i>BGN'000</i> | Other reserves <i>BGN'000</i> | Retained earnings / loss <i>BGN'000</i> | Total equity <i>BGN'000</i> |
|---|--|---|-------------------------------------|---|-----------------------------------|
| Balance as of 01.01.2022 | 84 500 | 4 375 | 8 007 | 1 940 | 98 822 |
| Profit/loss for the period | | | | 2 791 | 2 791 |
| Other comprehensive income | | (24) | | | (24) |
| Including from tax effect of the revaluation of property, plant and equipment | | | | | |
| Total comprehensive income | | (24) | | 2 791 | 2 767 |
| Issue of shares by the owners | | | 140 | (140) | |
| Dividends accrued | | | 140 | (140) | |
| Tantiemmes accrued | | | | | |
| Profit transferred to reserves | | | | | |
| Total amount of income and expenses recognised during the period | | | | | |
| Balance as of 31.12.2022 | 84 500 | 4 351 | 8 147 | 4 591 | 101 589 |
| Balance as of 01.01.2023 | 84 500 | 4 351 | 8 147 | 4 591 | 101 589 |
| Profit/loss for the period | | | | 4 282 | 4 282 |
| Other comprehensive income | | | | | |
| Total comprehensive income | | | | 4 282 | 4 282 |
| Issue of shares by the owners | | | 284 | (284) | |
| Total amount of income and expenses recognised during the period | | | 284 | (284) | |
| Balance as of 30.06.2023 | 84 500 | 4 351 | 8 431 | 8 589 | 105 871 |

Date of preparation: 25.07.2023
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/